WilmerHale Advises Notch Therapeutics on Collaboration With Allogene Therapeutics

WilmerHale Advises Notch Therapeutics on Collaboration With Allogene Therapeutics

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On November 5, 2019, Notch Therapeutics and Allogene Therapeutics announced a collaboration to research and develop induced pluripotent stem cell (IPSC)-derived allogeneic therapies for hematologic cancer indications. Allogene Therapeutics is taking a 25% stake in Notch Therapeutics and paying $10 million up front in an exclusive deal to research and develop new induced pluripotent stem cell (IPSC)-based allogeneic CAR T therapies, initially in non-Hodgkin lymphoma, leukemia and multiple myeloma. Notch Therapeutics, a Toronto-based immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of diseases of high unmet medical need, stands to make millions of dollars more in milestone payments and royalties should any commercial products emerge from the collaboration.

Partners Steven Barrett and Brian Johnson led the WilmerHale team, which included Tim Kulis and Howell Ma.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel